AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|
22.6 C
New York
Monday, June 22, 2026

Tag: treatments

newssourceFORcompanyinformationcontent1marketreleases

GBK & Sydenham Host Star-Studded Pre-ESPY Longevity Talent Lounge at Sydenham Clinic in Beverly Hills

The World's Top Athletes Received This Year's Hottest Gifts and Trips in Celebration on the Eve of One of the Biggest Nights in Sports LOS...

G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise

"Highlighting Strategic Alliances and Innovation, the Global GPCR Targeting Market Report Explores the Role of GPCRs in Drug Discovery and Therapeutics, Featuring Key Players...

Michael Kramer and Lilly Pulitzer Unveil Vibrant Garden-Inspired Cottages in collaboration with Lee Jofa and Benjamin Moore at Nantucket Hotel & Resort

NANTUCKET, Mass., July 16, 2025 /PRNewswire/ -- New York City-based interior designer Michael Kramer of Michael Thomas & Co. has teamed up with iconic...

A Statement from the Global Virus Network (GVN) on the Rapidly Escalating Measles Crisis in the U.S. and Worldwide

GVN is sounding the alarm over a sharp resurgence of measles cases in the United States and globally.

RxPreferred Launches My-RxP: Cutting Costs for Brand, Specialty, GLP-1, and Fertility Medications by Up to 60%

NASHVILLE, Tenn., July 16, 2025 /PRNewswire/ -- RxPreferred, a leading transparent pharmacy benefit administrator, is proud to announce the launch of My-RxP, an innovative medication...

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

AZ Integrative & Functional Medicine Offering EXOMIND: Trailblazing Technology Using Brain Stimulation for Depression and Optimize Mental Health

EXOMIND launch event slated for July 25 SCOTTSDALE, Ariz., July 15, 2025 /PRNewswire/ -- For those seeking to lessen their anxiety, treat depression or enhance...

New Bass Center Clinic and Infusion Center to Facilitate Healing

PALO ALTO, Calif., July 15, 2025 /PRNewswire/ -- Lucile Packard Children's Hospital Stanford, the cornerstone of Stanford Medicine Children's Health, is proud to announce...

Chalk River Laboratories Becomes First GLP-Certified Laboratory in Canada to Offer Pre-Clinical Radiopharmaceutical Studies

Following successful SCC audit, CNL is ready to perform pre-clinical studies for growing radiopharmaceutical industry as GLP-compliant laboratory 
Following successful SCC audit, CNL is ready to perform pre-clinical studies for growing radiopharmaceutical industry as GLP-compliant laboratory

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers